Patents by Inventor Frederick A. Valeriote
Frederick A. Valeriote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210221777Abstract: A pharmaceutically active mycathiozole analog or salt thereof is derived from naturally occurring mycathiozole. The analog or salt is useful in cancer treatment.Type: ApplicationFiled: January 14, 2021Publication date: July 22, 2021Inventors: Tyler A. Johnson, Colon V. Cook, Nicole L. McIntosh, Joseph D. Morris, Frederick A. Valeriote, JiaJiu Shaw, Phillip Crews, Mani Maheshwari
-
Patent number: 11020488Abstract: Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.Type: GrantFiled: March 13, 2018Date of Patent: June 1, 2021Assignees: The Regents of the University of California, Henry Ford Health SystemInventors: Phillip Crews, Frederick A. Valeriote, Sheng Lin, Erin P. McCauley, Nicholas Lorig-Roach, Karen Tenney
-
Publication number: 20200129631Abstract: Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.Type: ApplicationFiled: March 13, 2018Publication date: April 30, 2020Inventors: Phillip Crews, Frederick A. Valeriote, Sheng Lin, Erin P. McCauley, Nicholas Lorig-Roach, Karen Tenney
-
Patent number: 9409944Abstract: In particular, in alternative embodiments, the invention provides pharmaceutical compounds and formulations comprising a family of epoxyketone compounds, which include racemic mixtures or racemates, isomers, stereoisomers, diastereoisomers, derivatives and analogs, and methods for making and using them. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to treat, prevent, reverse and/or ameliorate an infection, disease or condition that can be ameliorated, treated, prevented or reversed by partially or completely inhibiting a chymotrypsin-like protease or a proteasome activity, including e.g.Type: GrantFiled: July 12, 2012Date of Patent: August 9, 2016Assignee: The Regents of the University of CaliforniaInventors: William H. Gerwick, Alban R. Pereira-Badilla, Tara Byrum, Frederick A. Valeriote, Michael Kenneth Gilson, Andrew T. Fenley, Bradley S. Moore, Andrew Kale, Hosana Debonsi
-
Publication number: 20140248333Abstract: In particular, in alternative embodiments, the invention provides pharmaceutical compounds and formulations comprising a family of epoxyketone compounds, which include racemic mixtures or racemates, isomers, stereoisomers, diastereoisomers, derivatives and analogs, and methods for making and using them. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to treat, prevent, reverse and/or ameliorate an infection, disease or condition that can be ameliorated, treated, prevented or reversed by partially or completely inhibiting a chymotrypsin-like protease or a proteasome activity, including e.g.Type: ApplicationFiled: July 12, 2012Publication date: September 4, 2014Applicants: JOSEPHINE FORD CANCER CENTER, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: William H. Gerwick, Alban R. Pereira-Badilla, Tara Byrum, Frederick A. Valeriote, Michael Kenneth Gilson, Andrew Fenley, Bradley S. Moore, Andrew Kale, Hosana M. Debonsi
-
Patent number: 8598313Abstract: In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG. 1) and apratoxin G (compound 7 of FIG. 1) and their stereoisomers, derivatives and analogs. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered in an amount sufficient to treat, prevent and/or ameliorate a disease or condition that can be ameliorated by decreasing or inhibiting cell growth, e.g., pathological, uncontrolled or unwanted cell growth, e.g., a cancer or a metastases, or any disease or condition (e.g., allergy) or infection having a hyperproliferative cell growth component.Type: GrantFiled: March 11, 2011Date of Patent: December 3, 2013Assignee: The Regents of the University of CaliforniaInventors: William H. Gerwick, Kevin Tidgewell, Frederick A. Valeriote
-
Publication number: 20130045925Abstract: In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG. 1) and apratoxin G (compound 7 of FIG. 1) and their stereoisomers, derivatives and analogs. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered in an amount sufficient to treat, prevent and/or ameliorate a disease or condition that can be ameliorated by decreasing or inhibiting cell growth, e.g., pathological, uncontrolled or unwanted cell growth, e.g., a cancer or a metastases, or any disease or condition (e.g., allergy) or infection having a hyperproliferative cell growth component.Type: ApplicationFiled: March 11, 2011Publication date: February 21, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: William H. Gerwick, Kevin Tidgewell, Frederick A. Valeriote
-
Publication number: 20030158088Abstract: The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.Type: ApplicationFiled: December 17, 2002Publication date: August 21, 2003Applicant: Advanced Research and Technology Institute, Inc.Inventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote
-
Patent number: 6573296Abstract: The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.Type: GrantFiled: April 16, 1999Date of Patent: June 3, 2003Assignee: Advanced Research and Technology Institute, Inc.Inventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote
-
Publication number: 20020019439Abstract: The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.Type: ApplicationFiled: April 16, 1999Publication date: February 14, 2002Inventors: PAUL A. GRIECO, D. JAMES MORRE, THOMAS H. CORBETT, FREDERICK A. VALERIOTE
-
Patent number: 6013626Abstract: A cryptophycin compound is provided having the structure: ##STR1## Further provided are methods of producing cryptophycins by total synthesis and methods of using cryptophycins in pharmaceuticals. It is a further object of this invention to use cryptophycins to inhibit the proliferation of mammalian cells. Moreover, methods of using cryptophycins to treat neoplasia is also provided.Type: GrantFiled: March 7, 1995Date of Patent: January 11, 2000Assignees: The University of Hawaii, Wayne State UniversityInventors: Richard E. Moore, Marcus A. Tius, Russell A. Barrow, Jian Liang, Thomas H. Corbett, Frederick A. Valeriote, Trimurtulu Golakoti, Thomas K. Hemscheidt
-
Patent number: 5965493Abstract: The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.Type: GrantFiled: May 1, 1997Date of Patent: October 12, 1999Assignees: Advanced Research and Technology Institute, Inc., The Board of Governors of Wayne State University, Purdue Reseach FoundationInventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote
-
Patent number: 5955423Abstract: A cryptophycin compound is provided having the structure: ##STR1## Further provided are methods for producing novel cryptophycins from the Nostoc sp. of blue-green algae (cyanobacteria). Pharmaceutical compositions comprising novel cryptophycins are also provided, as are methods for using cryptophycins to inhibit the proliferation of hyperproliferative cells. Further provided are methods for using cryptophycins to inhibit the proliferation of hyperproliferative cells with drug resistant phenotypes, and to treat pathological conditions, such as neoplasia.Type: GrantFiled: June 7, 1995Date of Patent: September 21, 1999Assignees: The University of Hawaii, Wayne State UniversityInventors: Richard E. Moore, Charles D. Smith, Gregory M. L. Patterson, Susan L. Mooberry, Thomas H. Corbett, Frederick A. Valeriote, Trimurtulu Golakoti
-
Patent number: 5952298Abstract: A cryptophycin compound is provided having the structure: ##STR1## Further provided are methods for producing novel cryptophycins from the Nostoc sp. of blue-green algae (cyanobacteria). Pharmaceutical compositions comprising novel cryptophycins are also provided, as are methods for using cryptophycins to inhibit the proliferation of hyperproliferative cells. Further provided are methods for using cryptophycins to inhibit the proliferation of hyperproliferative cells with drug resistant phenotypes, and to treat pathological conditions, such as neoplasia.Type: GrantFiled: June 7, 1995Date of Patent: September 14, 1999Assignees: The University Of Hawaii, Wayne State UniversityInventors: Richard E. Moore, Charles D. Smith, Gregory M.L. Patterson, Susan L. Mooberry, Thomas H. Corbett, Frederick A. Valeriote, Trimurtulu Golakoti
-
Patent number: 5849748Abstract: The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.Type: GrantFiled: June 13, 1997Date of Patent: December 15, 1998Assignee: Advanced Research and Technology Institute, Inc.Inventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote
-
Patent number: 5639712Abstract: Quassinoid compounds, compositions, and methods of using them for treating cells and solid tumors, and inhibiting plant growth.Type: GrantFiled: November 4, 1994Date of Patent: June 17, 1997Assignees: Indiana University Foundation, Purdue Research Foundation, Bd. of Governors of Wayne State Univ.Inventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote